ANMCO/SICI-GISE paper on antiplatelet therapy in acute coronary syndrome

European Heart Journal, Supplement

Volumn 16, Issue , 2014, Pages C2-C28

  De Luca, G ^j   Bolognese, Leonardo ^b   Valgimigli, Marco ^c   Ceravolo, Roberto ^d   Danzi, Gian Battista ^e,f   Piccaluga, Emanuela ^f   Rakar, Serena ^g   Cremonesi, Alberto ^h   Bovenzi, Francesco Maria ⁱ   Abbate, R ^j   Andreotti, F ^a   Biondi Zoccai, G ^a   Capodanno, D ^j   Caporale, R ^j   Capranzano, P ^j   Carrabba, N ^j   Casella, G ^j   Cavallini, C ^j   Colombo, P ^f   Conte, M R ^j   Cordone, S ^j   Del Pinto, M ^j   De Servi, S ^j   Di Lorenzo, E ^j   Di Pasquale, G ^j   Esposito, G ^j   Farina, R ^j   Fiscella, A ^j   Formigli, D ^j   Galli, S ^f   Giudice, P ^j   Gonzi, G ^j   Greco, C ^a   Grieco, N B ^f   La Vecchia, L ^j   Lazzari, M ⁱ   Lettieri, C ^j   Lettino, M ^j   Limbruno, U ^j   Lupi, A ^j   Macchi, A ^j   Marini, M ^j   Marzilli, M ^j   Montinaro, A ^j   Musumeci, G ^j   Navazio, A ^k   Olivari, Z ^j   Oltrona Visconti, L ^j   Oreglia, J A ^f   Ottani, F ^j   Parodi, G ^j   Pasquetto, G ^j   Patti, G ^a   Perkan, A ^g   Perna, G P ^j   Piscione, F ^j   Prati, F ^j   Ravasio, R ^f   Ronco, F ^j   Rossini, R ^j   Rubboli, A ^j   Saia, F ^j   Sardella, G ^a   Satullo, G ^j   Savonitto, S ^j   Sbarzaglia, P ^h   Scorcu, G ^j   Signore, N ^j   Tarantini, G ^j   Terrosu, P ^j   Testa, L ^f   Tubaro, M ^a   Valente, S ^j   Varbella, F ^l   Vatrano, M ^d   more..

^a EUROPEAN HOSPITAL   (Italy)

^b IRCCS POLICLINICO SAN DONATO   (Italy)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d PUGLIESE CIACCIO HOSPITAL   (Italy)

^e SANTA CORONA HOSPITAL   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g UNIVERSITY OF TRIESTE   (Italy)

^h MARIA CECILIA HOSPITAL   (Italy)

ⁱ CAMPO DI MARTE HOSPITAL   (Italy)

^j NONE   (Italy)

^k NONE   (Italy)

^l Division of Cardiology Rivoli Hospital   (Italy)

more..

Author keywords

Acute coronary syndrome; Antiplatelet agents; Aspirin; Cangrelor; Clopidogrel; Prasugrel; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; TICAGRELOR;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; CONSERVATIVE TREATMENT; CORONARY ARTERY SURGERY; DIABETES MELLITUS; HOSPITAL PATIENT; HUMAN; KIDNEY DISEASE; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 84925378562     PISSN: 1520765X     EISSN: 15542815     Source Type: Journal    
DOI: 10.1093/eurheartj/suu030     Document Type: Article

References (220)

1. Levine GN, Ali MN, Schafer AI. Antithrombotic therapy in patients with acute coronary syndromes. Arch Intern Med 2001;161:937-948.
2. Tran H, Anand SS. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. JAMA 2004;292:1867-1874.
3. Brilakis ES, Patel VG, Banerjee S. Medical management after coronary stent implantation: a review. JAMA 2013;310:189-198.
4. Schömig A, Neumann FJ, Kastrati A et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-1089.
5. Leon MB, Baim DS, Popma JJ et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting: Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339:1665-1671.
6. Albiero R, Hall P, Itoh A et al. Results of a consecutive series of patients receiving only antiplatelet therapy after optimized stent implantation. Comparison of aspirin alone versus combined ticlopidine and aspirin therapy. Circulation 1997;95:1145-1156.
7. Colombo A, Hall P, Nakamura S et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995;91:1676-1688.
8. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999;100:1667-1672.
9. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
10. Yusuf S, Mehta SR, Zhao F et al. Clopidogrel in Unstable angina to prevent Recurrent Events Trial Investigators. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 2003;107:966-972.
11. Jneid H, Bhatt DL,Corti R, Badimon JJ, Fuster V, Francis GS. Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study. Arch Intern Med 2003;163:1145-1153.
12. Khot UN, Nissen SE. Is CURE a cure for acute coronary syndromes? Statistical versus clinical significance. JAmColl Cardiol 2002;40:218-219.
13. Mehta SR, Yusuf S, Peters RJ et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-533.
14. Lotrionte M, Biondi-Zoccai GG, Agostoni P et al. Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention. Am J Cardiol 2007;100:1199-1206.
15. Kastrati A, Mehilli J, Neumann FJ et al. Intracoronary Stenting and Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT2randomized trial. JAMA 2006;295:1531-1538.
16. Angiolillo DJ, Guzman LA, Bass TA. Current antiplatelet therapies: benefits and limitations. Am Heart J 2008;156(2 Suppl.):S3-S9.
17. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J AmColl Cardiol 2007;49:1505-1516.
18. Parodi G, Marcucci R, Valenti R et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 2011; 306:1215-1223.
19. Bonello L, Armero S, Ait Mokhtar O et al. Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19∗2 loss of function polymorphism. J Am Coll Cardiol 2010; 56:1630-1636.
20. Bonello L, Camoin-Jau L, Armero S et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009;103:5-10.
21. Price MJ, Murray SS, Angiolillo DJ et al. GIFT Investigators. Influence of genetic polymorphisms on the effect of high-and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. J AmColl Cardiol 2012;59: 1928-1937.
22. Simon T, Verstuyft C, Mary-Krause M et al. FAST-MI Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-375.
23. Mega JL, Close SL, Wiviott SD et al. Cytochrome P-450 polymorphisms and response to clopidpgrel. N Engl J Med 2009;360:354-362.
24. Brandt JT, Close SL, Iturria SJ et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007;5:2429-2436.
25. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002;41:913-958.
26. Cattaneo M. The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects. Blood 2011;117:2102-2112.
27. Gilard M, Arnaud B, Cornily JC et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256-260.
28. Cuisset T, Frere C, Quilici J et al. Comparison of omeprazole and pantoprazole influence on high 150-mg clopidogrel maintenance dose: the PACA (Proton Pump Inhibitors and Clopidogrel Association) prospective randomized trial. J Am Coll Cardiol 2009;54:1149-1153.
29. O'Donoghue ML, Braunwald E, Antman EM et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009;374:989-997.
30. Lau WC,Waskell LA,Watkins PB et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003;107:32-37.
31. Abraham NS, Hlatky MA, Antman EM et al. ACCF/ACG/AHA. ACCF/ ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation 2010;122:2619-2633.
32. Bhatt DL, Cryer BL, Contant CF et al. COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909-1917.
33. Marcucci R, Paniccia R, Gori AM, Gensini GF, Abbate R. Bioequivalence in the real world is a complex challenge: the case of clopidogrel. J Am Coll Cardiol 2013;61:594-595.
34. Schömig A. Ticagrelor-is there need for a new player in the antiplatelet-therapy field? N Engl J Med 2009;361:1108-1111.
35. Gurbel PA, Bliden KP, Butler K et al. Randomized double-blind assessment of the ONSETand OFFSETof the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSETstudy. Circulation 2009;120:2577-2585.
36. Wiviott SD, Trenk D, Frelinger AL et al. PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007;116:2923-2932.
37. Mega JL, Close SL, Wiviott SD et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009; 119:2553-2560.
38. Wallentin L, James S, Storey RF et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010;376:1320-1328.
39. Wiviott SD, Antman EM, Braunwald E. Prasugrel. Circulation 2010; 122:394-403.
40. Bonello L, Pansieri M, Mancini J et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 2011;58:467-473.
41. Wiviott SD, Braunwald E, McCabe CH et al. TRITON TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015.
42. Wiviott SD, Braunwald E, McCabe CH et al. TRITON-TIMI 38 Investigators. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008;371:1353-1363.
43. HochholzerW, Wiviott SD, Antman EM et al. Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation 2011;123:2681-2689.
44. Wiviott SD, Desai N, Murphy SA et al. Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. Am J Cardiol 2011;108:905-911.
45. Angiolillo DJ, Bhatt DL, Gurbel PA, Jennings LK. Advances in antiplatelet therapy: agents in clinical development. Am J Cardiol 2009;103(3 Suppl.):40A-51A.
46. Berger JS. Aspirin, clopidogrel, and ticagrelor in acute coronary syndromes. Am J Cardiol 2013;112:737-745.
47. Wallentin L, Becker RC, Budaj A et al. PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057.
48. Schneider DJ. Mechanisms potentially contributing to the reduction in mortality associated with ticagrelor therapy. J Am Coll Cardiol 2011; 57:685-687.
49. Wittfeldt A, Emanuelsson H, Brandrup-Wognsen G et al. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. J Am Coll Cardiol 2013;61:723-727.
50. Alexopoulos D, Moulias A, Koutsogiannis N et al. Differential effect of ticagrelor versus prasugrel on coronary blood flow velocity in patients with non-ST-elevation acute coronary syndromeundergoing percutaneous coronary intervention: an exploratory study. Circ Cardiovasc Interv 2013;6:277-283.
51. Nylander S, Femia EA, Scavone M et al. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism. J Thromb Haemost 2013;11:1867-1876.
52. Becker RC, Bassand JP, Budaj A et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2011;32: 2933-2944.
53. Storey RF, Becker RC, Harrington RA et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J 2011;32: 2945-2953.
54. Hamm CW, Bassand JP, Agewall S et al. ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999-3054.
55. Steg PG, James SK, Atar D et al. for the Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569-2619.
56. Wouter Jukema J, Collet JP,De Luca L. Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel. Curr Med Res Opin 2012;28: 203-211.
57. http://clinicaltrials.gov/show/NCT01944800.
58. Bagnall AJ, Goodman SG, Fox KA et al. Canadian Acute Coronary SyndromeRegistry I and II Investigators; Canadian Global Registry of Acute Coronary Events (GRACE/GRACE2) Investigators. Influence of age on use of cardiac catheterization and associated outcomes in patients with non-ST-elevation acute coronary syndromes. Am J Cardiol 2009;103:1530-1536.
59. Lee TC, Goodman SG, Yan RT et al. Canadian Acute Coronary Syndromes I and II, Canadian Global Registry of Acute Coronary Events (GRACE/GRACE2) and the Canadian Registry of Acute Coronary Events (CANRACE) Investigators. Disparities in management patterns and outcomes of patients with non-ST-elevation acute coronary syndrome with and without a history of cerebrovascular disease. Am J Cardiol 2010;105:1083-1089.
60. Gogo PB Jr, Dauerman HL, Mulgund J et al. CRUSADE Investigators. Changes in patterns of coronary revascularization strategies for patients with acute coronary syndromes (from the CRUSADE Quality Improvement Initiative). Am J Cardiol 2007;99:1222-1226.
61. Di Chiara A, Fresco C, Savonitto S et al. BLITZ-2 Investigators. Epidemiology of non-STelevation acute coronary syndromes in the Italian cardiology network: the BLITZ-2 study. Eur Heart J 2006;27:393-405.
62. Olivari Z, Steffenino G, Savonitto S et al. The management of acute myocardial infarction in the cardiological intensive care units in Italy: the 'BLITZ 4 Qualità' campaign for performance measurement and quality improvement. Eur Heart J: Acute Card Care in press.
63. Steinhubl SR, Berger PB, Mann JT III et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-2420.
64. Sabatine MS, Cannon CP, Gibson CM et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005;294:1224-1232.
65. Bellemain-Appaix A, O'Connor SA, Silvain J et al. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. JAMA 2012;308: 2507-2516.
66. Lindholm D, Varenhorst C, Cannon CP et al. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J 2014 [Epub ahead of print].
67. De Servi S, Goedicke J, Schirmer A, Widimsky P. Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITONTIMI 38 trial. Eur Heart J Acute Cardiovasc Care 2014 [Epub ahead of print].
68. Montalescot G, Bolognese L, Dudek D et al. ACCOAST Investigators. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 2013;369:999-1010.
69. Valgimigli M, Minarelli M. Triple antiplatelet therapy in acute coronary syndromes. Drugs 2011;71:1703-1719.
70. Valgimigli M, Tebaldi M, Campo G et al. FABOLUS PRO Investigators. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial. JACC Cardiovasc Interv 2012;5:268-277.
71. Giugliano RP, White JA, Bode C et al. EARLY ACS Investigators. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 2009;360:2176-2190.
72. Stone GW, Ware JH, Bertrand ME et al. ACUITY Investigators. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. JAMA 2007;298:2497-2506.
73. Silvain J, Collet JP, Nagaswami Cet al. Composition of coronary thrombus in acute myocardial infarction. J Am Coll Cardiol 2011;57: 1359-1367.
74. Vlaar PJ, Svilaas T, Damman K et al. Impact of pretreatment with clopidogrel on initial patency and outcome in patients treated with primary percutaneous intervention for ST-segment elevation myocardial infarction. A systematic review. Circulation 2008;118: 1828-1836.
75. Koul S, Smith JG, Scherstén F, James S, Lagerqvist B, Erlinge D. Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Eur Heart J 2011;32:2989-2997.
76. Fefer P, Hod H, Hammermann H, Segev A et al. Usefulness of pretreatment with high-dose clopidogrel in patients undergoing primary angioplasty for ST-elevation myocardial infarction. Am J Cardiol 2009;104: 514-518.
77. Dangas G, Mehran R, Guagliumi G et al. HORIZONS-AMI Trial Investigators. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol 2009;54:1438-1446.
78. Bellemain-Appaix A, Brieger D, Beygui F et al. New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis. J Am Coll Cardiol 2010;56:1542-1551.
79. Montalescot G, Wiviott SD, Braunwald E et al. Prasugrelcompared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): doubleblind, randomised controlled trial. Lancet 2009;373:723-731.
80. Udell JA, Braunwald E, Antman EM, Murphy SA, Montalescot G, Wiviott SD. Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38). JACC Cardiovasc Interv 2014;7:604-612.
81. Steg PG, James S, Harrington RA et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 2010;122:2131-2141.
82. Serebruany VL. Ticagrelor FDA approval issues revisited. Cardiology 2012;122:144-147.
83. Kunadian V, James SK,Wojdyla DM et al. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). JACC Cardiovasc Interv 2013;6:671-683.
84. Armstrong PW, Siha H, Fu Y, Westerhout CM et al. ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy. Circulation 2012;125: 514-521.
85. Montalescot G, van't Hof AW, Lapostolle F et al. Pre-hospital Ticagrelor in ST-segment myocardial infarction. N Engl J Med 2014. doi: 10.1056/NEJMoa1407024.
86. De Servi S, Navarese EP, D'Urbano M, Savonitto S. Treating acute coronary syndromes with new antiplatelet drugs: the mortality issue with prasugrel and ticagrelor. Curr Med Res Opin 2011;27:2117-2122.
87. Parodi G, Valenti R, Bellandi B et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 2013;61:1601-1606.
88. Heestermans AA, van Werkum JW, Taubert D et al. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res 2008;122:776-781.
89. De Luca G, Suryapranata H, Stone GW et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005;293: 1759-1765.
90. De Luca G, Navarese E, Marino P. Risk profile and benefits from GPIIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: ameta-regression analysis of randomized trials. Eur Heart J 2009;30:2705-2713.
91. Montalescot G, Antoniucci D, Kastrati A et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. Eur Heart J 2007;28:443-449.
92. De Luca G, Ucci G, Cassetti E, Marino P. Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis. J Am Coll Cardiol 2009;53:1668-1673.
93. Montalescot G, Barragan P, WittenbergO et al. ADMIRAL Investigators. Abciximabbefore direct angioplasty and stenting in myocardial infarction regarding acute and Long-term follow-up. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-1903.
94. Ellis SG, Tendera M, de Belder MA et al. FINESSE Investigators. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008;358:2205-2217.
95. Dudek D, Siudak Z, Janzon M et al. EUROTRANSFER Registry Investigators. European registry on patients with ST-elevation myocardial infarction transferred for mechanical reperfusion with a special focus on early administration of abciximab-EUROTRANSFER Registry. Am Heart J 2008;156:1147-1154.
96. Rakowski T, Siudak Z, Dziewierz A et al. Early abciximab administration before transfer for primary percutaneous coronary interventions for ST-elevation myocardial infarction reduces 1-year mortality in patients with high-risk profile. Results from EUROTRANSFER registry. Am Heart J 2009;158:569-575.
97. Van't Hof AW, Ten Berg J, Heestermans T et al. Ongoing tirofiban in myocardial infarction evaluation (ON-TIME) 2 study group. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (ON-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet 2008;372:537-546.
98. Heestermans T, van't HofAW, ten BergJMet al. The golden hour of prehospital reperfusion with triple antiplatelet therapy: a sub-analysis from the Ongoing Tirofiban in Myocardial Evaluation 2 (ON-TIME 2) trial early initiation of triple antiplatelet therapy. Am Heart J 2010; 160:1079-1084.
99. Hanna EB, Chen AY, Roe MT, Wiviott SD, Fox CS, Saucedo JF. Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary intervention. JACC Cardiovasc Interv 2011; 4:1002-1008.
100. Kadakia MB, Desai NR, Alexander KP et al. National Cardiovascular Data Registry. Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry-GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines). JACC Cardiovasc Interv 2010;3:1166-1177.
101. Amsterdam EA, Peterson ED, Ou FS et al. Comparative trends in guidelines adherence among patients with non-ST-segment elevation acute coronary syndromes treated with invasive versus conservative management strategies: results from the CRUSADE quality improvement initiative. Am Heart J 2009;158:748-754.
102. Roe MT, White JA, Kaul P et al. Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY-ACS Trial. Circ Cardiovasc Qual Outcomes 2012;5:205-213.
103. Fox KA, Mehta SR, Peters R et al. Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events Trial. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in unstable angina to prevent recurrent ischemic events (CURE) trial. Circulation 2004;110:1202-1208.
104. Solomon MD, Go AS, Shilane D, Boothroyd DB, Leong TK, Kazi DS, Chang TI, Hlatky MA.Comparative effectiveness of clopidogrel inmedicallymanagedpatients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol 2014;63:2249-2257.
105. James SK, Roe MT, Cannon CP et al. PLATO Study Group. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ 2011;342:d3527.
106. RoeMT, Armstrong PW, Fox KA et al. TRILOGYACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012;367:1297-1309.
107. Hirsch A, Windhausen F, Tijssen JG et al. Invasive versus Conservative Treatment in Unstable Coronary Syndromes Investigators. Diverging associations of an intended early invasive strategy compared with actual revascularization, and outcome in patients with non-ST-segment elevation acute coronary syndrome: the problem of treatment selection bias. Eur Heart J 2009;30:645-654.
108. Fox KA, Clayton TC, Damman P et al. FIR Collaboration. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. J Am Coll Cardiol 2010;55: 2435-2445.
109. RoeMT, Goodman SG, Ohman EM et al. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. Circulation 2013;128: 823-833.
110. Wiviott SD, White HD,OhmanEMet al. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGYACS trial. Lancet 2013;382:605-613.
111. Swaminathan RV, Feldman DN. TRILOGYACS: prasugrel of benefit only after angiography? Lancet 2013;382:580-582.
112. Puymirat E, Simon T, Steg PG et al. USIK USIC 2000 Investigators, FAST MI Investigators. Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. JAMA 2012;308:998-1006.
113. Fokkema ML, James SK, Albertsson P et al. Population trends in percutaneous coronary intervention: 20 year results from the Swedish coronary angiography and angioplasty registry. J Am Coll Cardiol 2013; 61:1222-1230.
114. Holmes DR Jr, Kereiakes DJ, Kleiman NS, Moliterno DJ, Patti G, Grines CL. Combining antiplatelet and anticoagulant therapies. J Am Coll Cardiol 2009;54:95-109.
115. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71-86.
116. Kenaan M, SethM, Aronow HD,Wohns D, Share D,Gurm HS. for the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). The clinical outcomes of percutaneous coronary intervention performed without pre-procedural aspirin. J Am Coll Cardiol 2013; in press.
117. http://clinicaltrials.gov/show/NCT01813435.
118. Mehta SR, Tanguay JF, Eikelboom JW et al. CURRENT-OASIS 7 Trial Investigators. Double-dose versus standard-dose clopidogrel and highdose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010;376:1233-1243.
119. Boersma E, Harrington RA, Moliterno DJ et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002;359:189-198.
120. CannonCP, Harrington RA, James S et al.Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010;375:283-293.
121. Steg PG, Harrington RA, Emanuelsson H et al. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation 2013;128:1055-1065.
122. Stone GW, Witzenbichler B, Guagliumi G et al. HORIZONS-AMI Trial Investigators. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011;377:2193-2204.
123. Kastrati A, Neumann FJ, Schulz S et al. ISAR-REACT 4 Trial Investigators. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med 2011;365:1980-1989.
124. Shahzad A, Kemp I, Mars C et al. for the HEAT-PPCI Trial Investigators. Unfractionatedheparin versusbivalirudin inprimarypercutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet 2014. doi: 10.1016/S0140-6736(14)60924-7.
125. http://clinicaltrials.gov/ct2/show/NCT00976092?term=BRAVE+4&rank=1.
126. Wang Y, Wu B, Shu X. Meta-analysis of randomized controlled trials comparing intracoronary and intravenous administration of glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction. Am J Cardiol 2012;109:1124-1130.
127. Shimada YJ, Nakra NC, Fox JT, Kanei Y. Meta-analysis of prospective randomized controlled trials comparing intracoronary versus intravenous abciximab in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.AmJ Cardiol 2012;109:624-628.
128. Friedland S, Eisenberg MJ, Shimony A. Meta-analysis of randomized controlled trials of intracoronary versus intravenous administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention for acute coronary syndrome. Am J Cardiol 2011;108: 1244-1251.
129. Gu YL, Kampinga MA, Wieringa WG et al. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial. Circulation 2010;122:2709-2717.
130. Bertrand OF, Rodés-Cabau J, Larose E et al. Early Discharge after Transradial Stenting of CoronarY Arteries in Acute Myocardial Infarction (EASY-MI) Study Investigators. Intracoronary compared to intravenous Abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction undergoing transradial primary percutaneous coronary intervention: a two-by-two factorial placebo-controlled randomized study. Am J Cardiol 2010;105:1520-1527.
131. GurbelPA,Tantry US. Delivery of glycoprotein IIb/IIIa inhibitor therapy for percutaneous coronary intervention: why not take the intracoronary highway? Circulation 2010;121:739-741.
132. Deibele AJ, Jennings LK, Tcheng JE, Neva C, Earhart AD, Gibson CM. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial. Circulation 2010; 121:784-791.
133. Thiele H,Wöhrle J, Hambrecht R et al. Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial. Lancet 2012;379:923-931.
134. Desch S, Wöhrle J, Hambrecht R et al. Intracoronary versus intravenous abciximab bolus in patients with ST-segment elevation myocardial infarction: 1-year results of the randomized AIDA STEMI trial. JAmColl Cardiol 2013;62:1214-1215.
135. StoneGW, Maehara A, Witzenbichler B et al. INFUSE-AMI Investigators. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA 2012;307:1817-1826.
136. Casella G, Cassin M, Chiarella F et al. BLITZ-3 Investigators. Epidemiology and patterns of care of patients admitted to Italian Intensive Cardiac Care units: the BLITZ-3 registry. J Cardiovasc Med 2010;11: 450-461.
137. Rizzello V, Lucci D, Maggioni AP et al. IN-ACS Outcome Investigators. Clinical epidemiology, management and outcome of acute coronary syndromes in the Italian network on acute coronary syndromes (IN-ACS Outcome study). Acute Card Care 2012;14:71-80.
138. Casella G, Di Pasquale G, Oltrona Visconti L et al. Management of patients with acute coronary syndromes in real-world practice in Italy: an outcome research study focused on the use of ANTithRombotic Agents: the MANTRA registry. Eur Heart J Acute Cardiovasc Care 2013;2:27-34.
139. Szummer K, Lundman P, Jacobson SH et al. SWEDEHEART. Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEARTregister. J Intern Med 2010;268:40-49.
140. Santopinto JJ, Fox KA, Goldberg RJ et al. Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE). Heart 2003;89:1003-1008.
141. Naidu SS, KrucoffMW, Rutledge DR et al. Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCEVimplantation: results from the 8,061-patient XIENCE V United States study. JACC Cardiovasc Interv 2012;5: 626-635.
142. Basra SS, Tsai P, Lakkis NM. Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease. J Am Coll Cardiol 2011;58:2263-2269.
143. Palmer SC, Di Micco L, RazavianMet al. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012;156:445-459.
144. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzymeinhibitor therapy inpatients with endstage renal disease and an acute myocardial infarction. J Am Coll Cardiol 2003;42:201-208.
145. McCullough PA, Sandberg KR, Borzak S, Hudson MP, Garg M, Manley HJ. Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J 2002;144:226-232.
146. Sciahbasi A, Arcieri R, Quarto M et al. Impact of chronic aspirin and statin therapy on presentation of patients with acute myocardial infarction and impaired renal function. Prev Cardiol 2010;13:18-22.
147. Ethier J, Bragg-Gresham JL, Piera L et al. Aspirin prescription and outcomes in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2007;50:602-611.
148. Best PJ, Steinhubl SR, Berger PB et al. The efficacy and safety of shortand long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events during Observation (CREDO) trial. Am Heart J 2008; 155:687-693.
149. Keltai M, Tonelli M, Mann JF et al. Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. Eur J Cardiovasc Prev Rehabil 2007;14:312-318.
150. Small DS, Wrishko RE, Ernest CS II et al. Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease. J Clin Pharm Ther 2009;34:585-594.
151. Alexopoulos D, Panagiotou A, Xanthopoulou I et al. Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity. J Thromb Haemost 2011;9:2379-2385.
152. James S, Budaj A, Aylward P et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function. Results from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation 2010;122:1056-1067.
153. MontalescotG, Silvain J. Ticagrelor in the renal dysfunction subgroup: subjugated or substantiated? Circulation 2010;122:1049-1052.
154. Berger PB, Best PJ, Topol EJ et al. The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. Am Heart J 2005;149:869-875.
155. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000;355: 773-778.
156. Donahoe SM, Stewart GC, McCabe CH et al. Diabetes and mortality following acute coronary syndromes. JAMA 2007;298:765-775.
157. Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation 2011;123:798-813.
158. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005;54: 2430-2435.
159. Roffi M, Angiolillo DJ, Kappetein AP. Current concepts on coronary revascularization in diabetic patients. Eur Heart J 2011;32: 2748-2757.
160. Price MJ. Bedside evaluation of thienopyridine antiplatelet therapy. Circulation 2009;119:2625-2632.
161. Bonello L, Tantry US, Marcucci R et al. Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919-933.
162. Bonello L, De Labriolle A, Scheinowitz M et al. Emergence of the concept of platelet reactivity monitoring of response to thienopyridines. Heart 2009;95:1214-1219.
163. Laine M, Frère C, Toesca R et al. Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome. A pharmacodynamic randomised study. Thromb Haemost 2014;111:273-278.
164. Wiviott SD, Braunwald E, Angiolillo DJ et al. TRITON-TIMI 38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008;118:1626-1636.
165. Murphy SA, Antman EM, Wiviott SD et al. TRITON-TIMI 38 Investigators. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J 2008;29:2473-2479.
166. James S, Angiolillo DJ, Cornel JH et al. PLATO Study Group. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: A substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2010;31:3006-3016.
167. Roffi M, Chew DP, Mukherjee D et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-STsegment-elevation acute coronary syndromes. Circulation 2001; 104:2767-2771.
168. Tang WH, Lincoff AM. Diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa blockade: the triad revisited. Circulation 2004; 110:3618-3620.
169. Capodanno D, Angiolillo DJ. Antithrombotic therapy in the elderly. J Am Coll Cardiol 2010;56:1683-1692.
170. Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353:2373-2383.
171. Silvain J, Cayla G, Hulot JS et al. High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. Eur Heart J 2012;33:1241-1249.
172. Husted S, James S, Becker RC et al. PLATO Study Group. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes 2012;5:680-688.
173. Serebruany VL. Timing of thienopyridine loading and outcomes in the TRITON trial: the FDA Prasugrel Action Package outlook. Cardiovasc Revasc Med 2011;12:94-98.
174. Gurbel PA, Erlinge D, Ohman EM et al. TRILOGYACS Platelet Function Substudy Investigators. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA 2012;308:1785-1794.
175. Erlinge D, Gurbel PA, James S et al. Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mgin nonelderly patients: theGENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. J Am Coll Cardiol 2013;62:577-583.
176. Wrishko RE, Ernest CS 2nd, Small DS et al. Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel activemetabolite in TRITON-TIMI 38. J Clin Pharmacol 2009;49:984-998.
177. Erlinge D, Ten Berg J, Foley D et al. Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial. J Am Coll Cardiol 2012;60:2032-2040.
178. Guagliumi G, Stone GW, Cox DA et al. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 2004;110:1598-1604.
179. Dauerman HL. Percutaneous coronary intervention pharmacology: from a triangle to a square. J Am Coll Cardiol 2008;51:698-700.
180. Subherwal S, Bach RG, Chen AYet al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA guidelines) Bleeding Score. Circulation 2009;119:1873-1882.
181. Lawler PR, Filion KB, Dourian T, Atallah R, Garfinkle M, Eisenberg MJ. Anemia and mortality in acute coronary syndromes: a systematic review and meta-analysis. Am Heart J 2013;165:143-153.
182. Willis P, Voeltz MD. Anemia, hemorrhage, and transfusion in percutaneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction. Am J Cardiol 2009; 104(5 Suppl.):34C-38C.
183. Elbarouni B, Elmanfud O, Yan RT et al. Temporal trend of in-hospital major bleeding among patients with non ST-elevation acute coronary syndromes. Am Heart J 2010;160:420-427.
184. Valgimigli M, Campo G, Monti M et al. Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 2012;125:2015-2026.
185. Rubboli A, Sciahbasi A, Briguori C et al.WARfarin and coronary STENTing Registry. In-hospital management and outcome of patients on warfarin undergoing coronary stent implantation: results of the multicenter, prospective WARfarin and coronary STENTing (WAR-STENT) registry. J Invasive Cardiol 2013;25:170-176.
186. Dewilde WJ, Oirbans T, Verheugt FWet al. WOEST Study Investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013;381: 1107-1115.
187. Sarafoff N, Martischnig A, Wealer J et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol 2013;61:2060-2066.
188. http://clinicaltrials.gov/show/NCT01830543.
189. Roberts DI, Nawarskas JJ. Treatment options for patients with poor clopidogrel response. Cardiol Rev 2013;21:309-317.
190. Loh JP, Pendyala LK, Kitabata H et al. Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 2013;111:841-845.
191. Alexopoulos D, Xanthopoulou I, Deftereos S et al. In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome. Am Heart J 2014;167:68-76.
192. Payne CD, Li YG, Brandt JTet al. Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects. Platelets 2008;19:275-281.
193. Angiolillo DJ, Saucedo JF, Deraad R et al. SWAP Investigators. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of theSWAP(SWitching Anti Platelet) study. JAmColl Cardiol 2010;56: 1017-1023.
194. CapranzanoP,TamburinoC,CapodannoDetal. Plateletfunctionprofiles in the elderly: results of a pharmacodynamic study in patients on clopidogrel therapyandeffectsof switchingtoprasugrel5 mginpatientswith high platelet reactivity. Thromb Haemost 2011;106:1149-1157.
195. Trenk D, Stone GW, Gawaz M et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity in Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 2012;59:2159-2164.
196. Lhermusier T, Voisin S, Mejean S, Garcia C, Sié P, Carrié D. Switching patients from clopidogrel to prasugrel in acute coronary syndrome: effects of prasugrel loading dose on residual platelet reactivity. J Thromb Haemost 2012;10:1946-1949.
197. Nührenberg TG, Trenk D, Leggewie S et al. Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: platelet reactivity in an observational study. Platelets 2013;24:549-553.
198. Cuisset T, Gaborit B, Dubois N et al. Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy. Int J Cardiol 2013;168:523-528.
199. Diodati JG, Saucedo JF, French JK et al. Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients (TRIPLET): a randomized controlled trial. Circ Cardiovasc Interv 2013;6:567-574.
200. Alexopoulos D, Galati A, Xanthopoulou I et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol 2012;60:193-199.
201. Burke MA, Lee R, Fintel DJ. Early clopidogrel use in non-ST elevation acute coronary syndrome and subsequent coronary artery bypass grafting. Am Heart J 2011;161:832-841.
202. Brown C, Joshi B, Faraday N et al. Emergency cardiac surgery in patients with acute coronary syndromes: a review of the evidence and perioperative implications of medical and mechanical therapeutics. Anesth Analg 2011;112:777-799.
203. Hongo RH, Ley J, Dick SE et al. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol 2002;40:231-237.
204. Firanescu CE, Martens EJ, Schonberger JP et al. Postoperative blood loss in patients undergoing coronary artery bypass surgery after preoperative treatment with clopidogrel. A prospective randomised controlled study. Eur J Cardiothorac Surg 2009;36:856-862.
205. Herman CR, Buth KJ, Kent BA et al. Clopidogrel increases blood transfusion and hemorrhagic complications in patients undergoing cardiac surgery. Ann Thorac Surg 2010;89:397-402.
206. Kim JH, Newby LK, Clare RM et al. Clopidogrel use and bleeding after coronary artery bypass graft surgery. Am Heart J 2008;156: 886-892.
207. Vaccarino GN, Thierer J, Albertal M et al. Impact of preoperative clopidogrel in off pump coronary artery bypass surgery: a propensity score analysis. J Thorac Cardiovasc Surg 2009;137:309-313.
208. Filsoufi F, Rahmanian PB, Castillo JG et al. Clopidogrel treatment before coronary artery bypass graft surgery increases postoperative morbidity and blood product requirements. J Cardiothorac Vasc Anesth 2008;22:60-66.
209. Shim JK, Choi YS, Oh YJ et al. Effects of preoperative aspirin and clopidogrel therapy on perioperative blood loss and blood transfusion requirements in patients undergoing off-pump coronary artery bypass graft surgery. J Thorac Cardiovasc Surg 2007;134:59-64.
210. Berger JS, Frye CB, Harshaw Q et al. Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. J Am Coll Cardiol 2008;52: 1693-1701.
211. Mahla E, Suarez TA, Bliden KP et al. Platelet function measurementbased strategy to reduce bleeding and waiting time in clopidogreltreated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. Circ Cardiovasc Interv 2012;5:261-269.
212. Smith PK, GoodnoughLT, LevyJH et al. Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. J Am Coll Cardiol 2012; 60:388-396.
213. Held C, Asenblad N, Bassand JP et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol 2011;57:672-684.
214. Varenhorst C, Alström U, Scirica BM et al. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. J AmColl Cardiol 2012;60: 1623-1630.
215. Rossini R, Bramucci E, Castiglioni B et al. Coronary stenting and surgery: perioperative management of antiplatelet therapy in patients undergoing surgery after coronary stent implantation. G Ital Cardiol 2012;13:528-551.
216. Savonitto S, D'Urbano M, CaraccioloMet al. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth 2010;104:285-291.
217. Wessler JD, Saldana F, Giugliano RP. Bridging therapy after recent stent implantation: case report and review of data. Cardiovasc Revasc Med 2012;13:30-38.
218. Pickett AM, Taylor DA, Ackman ML. Prolonged infusion of eptifibatide as bridge therapy between bare-metal stent insertion and cardiovascular surgery: case report and review of the literature. Pharmacotherapy 2010;30:127e-133e.
219. Angiolillo DJ, FirstenbergMS, PriceMJ et al. BRIDGEInvestigators. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 2012;307:265-274.
220. Ferraris VA, Ferraris SP, Saha SP. Antiplatelet drugs: mechanisms and risksof bleedingfollowingcardiac operations. Int J Angiol 2011;20:1-18.